• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[干眼症——多专科疾病。第二部分:诊断程序与治疗]

[Dry eye syndrom--multispecialistic disease. Part two: diagnostic procedure and treatment].

作者信息

Nowak Mariusz, Marek Bogdan, Kajdaniuk Dariusz, Siemińska Lucyna, Kos-Kudła Beata, Nowak Katarzyna, Głogowska-Szelag Joanna

出版信息

Wiad Lek. 2011;64(1):49-55.

PMID:21812364
Abstract

The authors present the review of the literature concerning on the diagnostic procedure and current treatment of the dry eye, including anti-inflammatory treatment. To diagnosis of the dry eye syndrome is based on the combination of clinical symptoms and clinical tests. These clinical tests evaluate tear clearance, tear stability, ocular surface integrity, tear osmolarity and conjunctival cytology. Measurement of tear osmolarity might provide a "gold standard" of diagnosis, but a practical tear osmolarity test is not yet widely available. Measurement of tear film instability by means of a TBUT test has good overall accuracy and may be more repeatable than many other diagnostic tests. The first step in managing the disease is to identify the underlying etiology and to try to eliminate it and/or treat it. Inflammation and the interruption of the inflammatory cascade seem to be the main focus in the treatment of dry eye, giving the anti-inflammatory therapy a new critical role.

摘要

作者对有关干眼诊断程序和当前治疗方法(包括抗炎治疗)的文献进行了综述。干眼综合征的诊断基于临床症状和临床检查的结合。这些临床检查评估泪液清除、泪液稳定性、眼表完整性、泪液渗透压和结膜细胞学。泪液渗透压测量可能提供诊断的“金标准”,但实用的泪液渗透压测试尚未广泛应用。通过泪膜破裂时间(TBUT)测试测量泪膜稳定性具有良好的总体准确性,并且可能比许多其他诊断测试更具可重复性。治疗该疾病的第一步是确定潜在病因并尝试消除和/或治疗它。炎症以及炎症级联反应的中断似乎是干眼治疗的主要重点,这赋予了抗炎治疗新的关键作用。

相似文献

1
[Dry eye syndrom--multispecialistic disease. Part two: diagnostic procedure and treatment].[干眼症——多专科疾病。第二部分:诊断程序与治疗]
Wiad Lek. 2011;64(1):49-55.
2
Performance of tear osmolarity compared to previous diagnostic tests for dry eye diseases.泪液渗透压与其他干眼病诊断测试的性能比较。
Curr Eye Res. 2010 Jul;35(7):553-64. doi: 10.3109/02713683.2010.484557.
3
Tear osmolarity measurement using the TearLab Osmolarity System in the assessment of dry eye treatment effectiveness.使用 TearLab 渗透压系统测量泪液渗透压评估干眼治疗效果。
Cont Lens Anterior Eye. 2010 Apr;33(2):61-7. doi: 10.1016/j.clae.2010.01.003. Epub 2010 Feb 12.
4
Clinical utility of objective tests for dry eye disease: variability over time and implications for clinical trials and disease management.干眼疾病客观测试的临床实用性:随时间的变化及其对临床试验和疾病管理的影响。
Cornea. 2012 Sep;31(9):1000-8. doi: 10.1097/ICO.0b013e318242fd60.
5
[Dry eye syndrome--multispecialistic disease. Part one: Pathogenesis, signs, classification].[干眼症——多专科疾病。第一部分:发病机制、体征、分类]
Wiad Lek. 2010;63(4):374-86.
6
A comparative study to assess the clinical use of Fluorescein Meniscus Time (FMT) with Tear Break up Time (TBUT) and Schirmer's tests (ST) in the diagnosis of dry eyes.一项比较研究,旨在评估荧光素半月皱襞时间(FMT)与泪膜破裂时间(TBUT)及泪液分泌试验(ST)在干眼症诊断中的临床应用。
Eye (Lond). 2002 Sep;16(5):594-600. doi: 10.1038/sj.eye.6700177.
7
Ocular surface and tear functions after topical cyclosporine treatment in dry eye patients with chronic graft-versus-host disease.慢性移植物抗宿主病干眼症患者局部应用环孢素后的眼表及泪液功能
Bone Marrow Transplant. 2008 Feb;41(3):293-302. doi: 10.1038/sj.bmt.1705900. Epub 2007 Nov 5.
8
Correlation of tear inflammatory cytokines and matrix metalloproteinases with four dry eye diagnostic tests.泪液炎症细胞因子和基质金属蛋白酶与四种干眼诊断试验的相关性。
Invest Ophthalmol Vis Sci. 2012 Mar 21;53(3):1512-8. doi: 10.1167/iovs.11-7627.
9
Tear film osmolarity measurements in dry eye disease using electrical impedance technology.干眼疾病中使用电阻抗技术测量泪膜渗透压。
Cornea. 2011 Dec;30(12):1289-92. doi: 10.1097/ICO.0b013e31821de383.
10
Dry eyes: etiology and management.干眼症:病因与治疗
Curr Opin Ophthalmol. 2008 Jul;19(4):287-91. doi: 10.1097/ICU.0b013e3283023d4c.